-
Something wrong with this record ?
Low-molecular weight chitosan enhances antibacterial effect of antibiotics and permeabilizes cytoplasmic membrane of Staphylococcus epidermidis biofilm cells
P. Kašparová, M. Zmuda, E. Vaňková, O. Maťátková, J. Masák
Language English Country United States
Document type Journal Article
Grant support
CZ.2.16/3.1.00/24503
Operational Programme Prague - Competitiveness
NPU I LO1601
National Programme of Sustainability I
- MeSH
- Anti-Bacterial Agents pharmacology MeSH
- Anti-Infective Agents * MeSH
- Biofilms MeSH
- Cell Membrane MeSH
- Chitosan * pharmacology MeSH
- Microbial Sensitivity Tests MeSH
- Molecular Weight MeSH
- Staphylococcus epidermidis MeSH
- Publication type
- Journal Article MeSH
This study evaluated the effect of low-molecular weight chitosan on Staphylococcus epidermidis, a common colonizer of joint implants and other prosthetic devices. We have also attempted to elucidate its mechanism of action. Chitosan was found to be effective against both the planktonic and biofilm cells (MIC80 35-40 mg/L; MBIC80 40-150 mg/L), in contrast to the antibiotics erythromycin and tetracycline with no antibiofilm activity (MBIC80 not found). In combination, chitosan had an additive effect with antibiotics on suspension growth of S. epidermidis (FICi 0.7-1.0), and the combinatory action caused a complete inhibition of biofilm metabolic activity in some cases. In addition, chitosan caused rapid cellular damage and enhanced antihaemolytic activity of tetracycline in combination towards S. epidermidis biofilm cells. Chitosan efficiently inhibited S. epidermidis growth acting via cell membrane damage, yet the extent of antimicrobial and antibiofilm activities was quite strain-specific. It was proved to be a very efficient antimicrobial agent worth further examination as a potent candidate in pharmaceutical research. Apart from antimicrobial activity, it also acted as antivirulence enhancing agent which is a very promising strategy for alternative infectious diseases treatment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21029460
- 003
- CZ-PrNML
- 005
- 20230601084849.0
- 007
- ta
- 008
- 211206s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-021-00898-6 $2 doi
- 035 __
- $a (PubMed)34291404
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kašparová, Petra $u Department of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice 166 28, Prague, Czech Republic. kasparop@vscht.cz
- 245 10
- $a Low-molecular weight chitosan enhances antibacterial effect of antibiotics and permeabilizes cytoplasmic membrane of Staphylococcus epidermidis biofilm cells / $c P. Kašparová, M. Zmuda, E. Vaňková, O. Maťátková, J. Masák
- 520 9_
- $a This study evaluated the effect of low-molecular weight chitosan on Staphylococcus epidermidis, a common colonizer of joint implants and other prosthetic devices. We have also attempted to elucidate its mechanism of action. Chitosan was found to be effective against both the planktonic and biofilm cells (MIC80 35-40 mg/L; MBIC80 40-150 mg/L), in contrast to the antibiotics erythromycin and tetracycline with no antibiofilm activity (MBIC80 not found). In combination, chitosan had an additive effect with antibiotics on suspension growth of S. epidermidis (FICi 0.7-1.0), and the combinatory action caused a complete inhibition of biofilm metabolic activity in some cases. In addition, chitosan caused rapid cellular damage and enhanced antihaemolytic activity of tetracycline in combination towards S. epidermidis biofilm cells. Chitosan efficiently inhibited S. epidermidis growth acting via cell membrane damage, yet the extent of antimicrobial and antibiofilm activities was quite strain-specific. It was proved to be a very efficient antimicrobial agent worth further examination as a potent candidate in pharmaceutical research. Apart from antimicrobial activity, it also acted as antivirulence enhancing agent which is a very promising strategy for alternative infectious diseases treatment.
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 12
- $a antiinfekční látky $7 D000890
- 650 _2
- $a biofilmy $7 D018441
- 650 _2
- $a buněčná membrána $7 D002462
- 650 12
- $a chitosan $x farmakologie $7 D048271
- 650 _2
- $a mikrobiální testy citlivosti $7 D008826
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a Staphylococcus epidermidis $7 D013212
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Zmuda, Martin $u Department of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice 166 28, Prague, Czech Republic
- 700 1_
- $a Vaňková, Eva $u Department of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice 166 28, Prague, Czech Republic
- 700 1_
- $a Maťátková, Olga $u Department of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice 166 28, Prague, Czech Republic $7 jo2017970315
- 700 1_
- $a Masák, Jan $u Department of Biotechnology, University of Chemistry and Technology in Prague, Technická 5, Prague 6 - Dejvice 166 28, Prague, Czech Republic
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 66, č. 6 (2021), s. 983-996
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34291404 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211206 $b ABA008
- 991 __
- $a 20230601084842 $b ABA008
- 999 __
- $a ok $b bmc $g 1731460 $s 1150013
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 66 $c 6 $d 983-996 $e 20210721 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- GRA __
- $a CZ.2.16/3.1.00/24503 $p Operational Programme Prague - Competitiveness
- GRA __
- $a NPU I LO1601 $p National Programme of Sustainability I
- LZP __
- $a Pubmed-20211206